top of page

Fate Therapeutics, Inc. (XNAS:FATE) In-Depth Stock/Fundamental/Options Analysis Today

Primary Facts

FATE

Name:

FATE THERAPEUTICS, INC. (XNAS:FATE)

Sector:

- 74697.00K

Industry:

Biotechnology

CEO:

Mr. John Wolchko

Total Employees:

449

Our Technological Advancement Rating

Our Rating:

B

Technological advancement compared to industry is 31.95% higher

ANALYSIS OF ALL CRITICAL FACTORS & RISKS RELATED TO THE STOCK & FUNDAMENTAL/LONG-TERM ANALYSIS OF FATE THERAPEUTICS, INC.(FATE) AS PER DATA ANALYSIS OF LAST 3 YEARS AND COMPARISON WITH COMPETITORS/PEERS, AND BIOTECHNOLOGY INDUSTRY. DATE: 07/09/2022

Primary Targets/Price Insights

Previous Close ($) :

26.72

One Month Price Target:

$26.97

Six Month Price Target :

$28.22

Likely Price in One Year's Time:

Ticker:

$29.73

Likely Trading Range Today Under (Normal Volatility)
 

$26.54

Price Upper limit ($) :

$27.

Price Lower limit ($) :

Crash Risk Prep/Key Price Levels (High Volatility/Risk)

Price, as per data analysis, isn't likely to fall below:

Today:

$23.95

                                                               This week:

$20.53

                                                        This month :

$14.35

Other Primary facts

Market Cap:

2.45B

Market Cap Classification:

Mid Cap

Number of Shares

IPO Date:

97.00M

Best/Worst Daily Performance (Last 3+ Years)
 

Highest Daily Appreciation:

37.8%

-21.74%

Worst Daily Decline:

Our Options Trading Entry Points

Iron Condor entry points for options expiring in 1 week's time

Low risk (<2%) entry points

Buy Call:

Sell Call:

Buy Put:

Sell Put:

$39.55

$33.61

$13.89

$19.83

Medium risk (<10%) entry points

Buy Call

Sell Call

$31.68

Buy Put:

Sell Put:

$30.41

$21.75

$23.03

These entry points can be used for other strategies, such as butterflies, straddles, etc.

Risk-Adjusted returns (Sharpe Ratio) of

FATE

Sharpe Ratio:

3.36%

Comparison:

FATE, is amongst the top 20% stocks with highest risk-adjusted returns

Sharpe ratio is 72.69% higher than the industry

& ratio is 47.32% higher than the market/S&P 500 average

Average Returns/Yield of

FATE

Daily returns:

0.18%

Weekly returns:

0.91%

Monthly returns:

3.62%

Yearly returns:

25.22%

Comparison of returns:

Average annual returns/yield (last 3 years) is 72.35% above industry average

Classification:

FATE, is amongst the top 20% highest yielding stocks in terms of daily returns

Results of T-Test of Returns:

0.62

Statistical test of Returns:

FATE has yielded returns statistically similar to the market

SHARPE ratio explained.png

Volatility (measured by Standard Deviation)

Daily Volatility:

5.13%

Weekly Volatility:

11.47%

Monthly Volatility:

22.95%

Yearly Volatility:

79.48%

Volitlilty of last five days (Measured by Standard Deviation) 

Average Volatility of this Week:

2.94%

Volatility in last five trading days has been -42.77% below long-term volatility

Value at Risk Analysis (VaR)

Daily VaR:

-10.36%

Weekly VaR:

-23.16%

Monthly VaR:

-46.31%

How Much Can the price of

FATE

Decline in a Recession?

Likely price decline in a recession: 

Base case (decline):

-39%

Worst case (decline):

>85%

This translates to price declining to:

$16.33

This translates to price declining to:

$4.01

Severe Crash Probability

Risk of crash in next 6/12 months: Very high (>70%)

What is Value at Risk (VaR)?

VaR explained figure

Risk Fundamentals

FATE is a 226.88% riskier investment compared to the market/S&P 500 & is 180.04% riskier than Nasdaq (IXIC)

Risk (measured by volatility) is 7.92% above industry average

Overall, it is amongst the top 50% most risky stocks

Beta Examination of

FATE

Beta in relation to market/S&P 500--1.67

Expected beta in 1 year's time:

1.161

Expected beta in 3 year's time:

1.642

Unlevered (debt free) Beta:

-

Beta in relation to Nasdaq (XNAS):

1.614

Beta in relation to all global stocks::

1.11

Beta Comparison & Analysis

Beta of competitors/peers::

1.314

Beta is 27.44% higher than peers

Average Industry Beta: 

1.152

Beta is 45.34% above industry average

Sustainable Growth Rate Analysis

Sustainable growth rate for this stock/firm:

-

-

Alpha provided | Alpha Analysis 

Alpha provided:

0.289

Alpha is 103.43% above industry average alpha yield

Alpha is 1837% higher than market/& is unsustainably high

Analysis of Cost of Capital of

FATE

Equity cost of capital:

0.146

Equity cost of capital is 32.40% above industry mean WACC

Unlevered (without debt) cost of capital:  

-

Before-tax cost of debt:

0.37%

After-tax cost of debt:

0.29%

Overall debt rating:

Highest AAA investment grade

Weighted average cost of capital (WACC):

0.29%

WACC is 40.27% above industry mean WACC

Key Per-Share Metrics & Analysis

Revenue per share:

$0.65

Revenue growth rate per share of (3Y):

4.09

Annual revenue growth rate is 22.85% above the industry average

EPS:

-$2.44

Expected Annual growth rate of  EPS (3Y):

15.87%

Expected future EPS growth rate is 59.00% higher than the Biotechnology industry

Free cash flow (FCF) per share:

-

-

-

Debt per share

$1.11

EBITDA per share

-$2.32

Valuation Analysis Today of

FATE

P/E Ratio:

-

P/E Ratio of Competitors/Peers:

134.55

-

-

FATE is -112.20% undervalued if valued using industry average P/E ratio

-

-

P/S (Price to Sales ratio):

41.06

Price to sales ratio is 1.38% above the industry mean

P/B (Price to book value ratio):

4.09

-

-

Net income growth rate (3Y):

117.29%

Net income growth rate is 66.17% higher than the average industry net income growth rate

Dividend Analysis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividend History:

--$0.00

--$0.00

--$0.00

--$0.00

--$0.00

--$0.00

-

In-depth Debt & Leverage Analysis

Debt to equity ratio:

17.04%

Net debt to equity ratio:

7.70%

Debt to assets ratio:

12.57%

Net debt to assets ratio:

5.68%

Debt-to-asset ratio is -70.17% below industry average

Ability to repay debt:

Interest coverage ratio:

-537.52

Interest coverage ratio is 354.20% more than industry average

Looking forward:

Debt growth rate:

18.01%

Annual debt growth is -87% lower than industry average debt growth rate

Debt repayment rate in last quarter: 0.00%

Analysis of Key Statistics  

Correlation of price movement with the market:

0.486

Statistical significance of correlation:

FATE has a statistically significant correlation with the market

Average Correlation of  the industry with the market:

0.34

Stock price is 42.83% more correlated with the market, compared to the industry average correlation

R Squared (percentage of price movement explained by movement of the market): 

0.34

Correlation of price movement with Nasdaq (^IXIC):

-0.063

Covariance  of price movement with the market:

-0.187

Kurtosis 

5.917

Returns have moderate fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns

Skewness of returns:

0.775

Returns are right (positive) skewed; mean returns are greater than median and mode returns

Fundamental Analysis & Dupont Analysis of

FATE

Gross Profit Margin Ratio:

100%

Operating Profit Margin Ratio:

-388.55%

Operating profit margin is -9.36% lower than the industry

Net Profit Margin Ratio:

100%

Effective Tax Rate:

-

-

Dupont Method

Net Profit Margin

Return on Equity Ratio (ROE):

×

ROA

=

×

-36.75%

Return on equity (ROE) is -35.91% lower than the industry

Financial Leverage

Asset Turnover Ratio (ROA):

-27.12%

Return on assets (ROA) is 32.90% higher than the industry

Financial Leverage:

1.1x

Current Ratio:

7.69

Current ratio is -5.01% below industry average

Cash Conversion Cycle (days):

0

-

The remaining useful life of property plant & equipment is: 3.2 years

Stock based compensation to net income ratio:

-8.31%

In-depth Efficiency  Analysis

Revenue generated per employee:

140.6K

Each employee generates -91% less revenue than industry average revenue per employee

EBITDA generated per employee: 

- 500.4K

Each employee generates -230% less EBITDA than industry average revenue per employee

Profit generated per employee: 

- 518.4K

Each employee generates -505% less net income/profit than industry average revenue per employee

Free cash flow (FCF) generated per employee: 

- 166.4K

Each employee generates -213% less free cash flow than industry average revenue per employee

Assets/Capital per employee

577.5K

Each employee generates -213% less free cash flow than industry average revenue per employee

Research & Development (R&D) Analysis

Research & development (R&D) investment growth rate-- 71.56%

Growth rate in R&D investment/expenditure is -2094.62% lower than the industry

Competitors/Peer firms of 

FATE

XLRN

BridgeBio Pharma, Inc. (XNAS:BBIO)

Tilray Brands, Inc. (XNAS:TLRY)

CHANGE HEALTHCARE INC. (XNAS:CHNG)

MIRATI THERAPEUTICS, INC. (XNAS:MRTX)

SOTERA HEALTH COMPANY (XNAS:SHC)

ARROWHEAD PHARMACEUTICALS, INC. (XNAS:ARWR)

HALOZYME THERAPEUTICS, INC. (XNAS:HALO)

GWPH

Current Analyst Ratings

Strong buy�13%

Buy�13%

Hold�0%

Sell�0%

Strong sell�0%

Overall analyst sentiment is: Strong buy

Income Statement

Period:

TTM

Date:

3/31/22

Revenue:

63.12M

Cost of Revenue:

Gross Profit:

R&D Expense

General & Admin Expenses:

Selling, General & Admin Expenses

Sales and Marketing Expenses

Other Expenses :

Operating Expenses :

Cost & Expenses :

Interest Income:

Interest Expenses:

Depreciation & Amortization:

EBITDA:

Operating Income:

Other Income Expenses:

Income Before Tax:

Income Tax Expense:

Net Income:

Balance Sheet

Date:

Calendar Year:

Period:

Cash & Cash Equivalents:

Short Term Investments:

Cash & Short Term Investments:

Net Receivables:

Inventory:

Other Current Assets:

Total Current Assets:

PP&E:

Goodwill: 

Intangible Assets: 

Long Term Investments: 

Tax Assets: 

Other Non-Current Assets: 

Total Non-Current Assets: 

Other Assets: 

Total Assets: 

Accounts Payable: 

Short Term Debt:

Tax Payables:

Deferred Revenue:

Other Current Liabilities:

Total Current Liabilities:

Long Term Debt:

Other Non-Current Liabilities:

Total Non Current Liabilities:

Other Liabilities:

Total Liabilities:

Common Stock:

Retained Earnings:

Accumulated Other Comprehensive Loss:

Other Total Stockholders' Equity:

Total Stockholders' Equity:

Total Liabilities and Stockholders' Equity:

Total Investments:

Total Debt:

Net Debt:

-

17.07M

242.81M

65.56M

65.56M

-

-

308.37M

1.35M

418.00K

7.65M

- 224682.00K

- 245251.00K

- 232752.00K

- 232752.00K

-

- 232752.00K

Statement of Cash Flow

Date:

Period:

2.76M

Differed Income Tax :

-

Stock Based Compensation :

19.33M

Change in Working Capital :

- 11126.00K

Accounts Receivables:

- 5174.00K

Other Working Capital:

- 52.00K

Other Non-Cash Items:

- 9889.00K

Net Cash Provided by Operating Activities:

- 64613.00K

Investments in PP&E:

- 10084.00K

Net Acquisitions:

-

Purchases of Investments:

- 132166.00K

Sales/Maturities of Investments:

Other Investing Activities:

​Net Cash Used for Investing Activities:

Debt Repayment:

Common Stock Issued:

Common Stock Repurchased:

Dividend Paid:

Other Financing Activities:

Net Cash Used Provided by Financing Activities:

Effect of FOREX on Changes in Cash:

Net Changes in Cash:

Cash at End of Period:

Cash at Beginning of Period:

Operating Cash Flow:

Capital Expenditure:

Free Cash Flow (FCF):

3/31/22

2022

Q1

64.74M

509.03M

573.77M

13.85M

-

11.45M

599.08M

167.33M

-

-

67.94M

-

24.04M

259.31M

-

858.39M

11.44M

5.58M

-

22.58M

38.31M

77.91M

107.94M

16.61M

147.08M

-

224.99M

97.00K

- 834773.00K

- 2850.0K

1.47B

March 31, 2022 at 6:00:00 AM

308.37M

633.39M

858.39M

576.97M

113.52M

48.8M

135.22M

-

- 7026.00K

-

-

-

-

2.80M

2.80M

-

- 68842.00K

79.97M

148.81M

- 64613.00K

- 10084.00K

- 74697.00K

Our Proprietary Portfolio Rating

Our Rating:

A+

Portfolio rating_explained.png
Tech rating_explained.png
Alpha explained.png

Price Forecast/Expected Price in Next 5 Years of

FATE

2023

2024

2025

2026

2027

$29.82

$33.18

$36.91

$41.06

$45.68

Woman Climber

SUPPORT US ON PATREON! 

Subscribe to stay updated on emerging risks and trends, so your capital, portfolio, and positions are protected!​

Thanks for submitting!

©Risk Concern 2022. All Rights Reserved. 
Risk Disclaimer: Trading in financial markets and cryptocurrencies is a risky activity and includes the risk of losing some, or all, of your investment amount. It is not suitable for all investors. The reports and data provided by risk concern are for informational purposes only. Risk concern and all associated with it shall not be responsible for any losses caused by the information or viewpoints presented on risk concern.

Risk Concern 16A Avenue, Edmonton, Alberta, Canada (T6w1Y2)

bottom of page